• News
  • SAN DIEGO
  • Finance

Isis Pharma shares rise on Kynamro approval

Shares of Isis Pharmaceuticals Inc. soared Wednesday on news that the U.S. Food and Drug Administration approved its new drug application for its Kynamro cholesterol drug.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
40.71
  -1.57  
- 3.71%
1,923,195,000
62.66
22.25

Insider Trade Data

Date Insider Shares Type Value
09/19/2014 Isis, Pharmaceuticals Inc 7,700 Sell $321,048
09/02/2014 O, Neil Patrick R 1,500 Sell $60,660
09/02/2014 O, Neil Patrick R 1,500 Exchange $15,435
09/02/2014 Parshall, B Lynne 11,071 Sell $445,507
09/02/2014 Parshall, B Lynne 11,071 Exchange $112,574

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chief Executive Officer, Founder, President, Chairman

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Subscribe Today!